Tags

Type your tag names separated by a space and hit enter

Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes.
Clin Biochem. 2009 May; 42(7-8):562-9.CB

Abstract

OBJECTIVES

Elevated advanced glycation endproducts (AGEs) are implicated in diabetic complications. Methylglyoxal-derived hydroimidazolone (MG-H) is one of the most abundant AGEs in vivo. Our objective was to develop a time-saving, specific method to measure free MG-H in plasma and determine its levels in complication-free young individuals with Type 1 diabetes (T1DM). The relationship of plasma free MG-H to hemoglobin A1C (A1C) and plasma methylglyoxal levels was also determined.

DESIGN AND METHODS

A solid phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed, and free plasma MG-H levels were measured in 40 T1DM patients (DM group), aged 6-21 years, and 11 non-diabetics (ND group), 6-22 years. Methylglyoxal was measured using LC-MS/MS and A1C by a Tosoh G7 high-performance liquid chromatograph.

RESULTS

Our method showed high recovery, sensitivity and short run-time. Plasma free MG-H (nmol/L) was higher (p<0.001) in the DM group (1318+/-569; mean+/-standard deviation) as compared to the ND group (583+/-419). Within the DM group, plasma free MG-H did not correlate with plasma methylglyoxal or A1C.

CONCLUSIONS

Our LC-MS/MS method to measure free MG-H in plasma may be useful for future clinical application. The increased levels of free MG-H observed in individuals with TIDM are not merely the result of short term changes in glucose or methylglyoxal, but may reflect long-term alterations to tissue proteins.

Authors+Show Affiliations

Division of Biochemical Pathology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19154730

Citation

Han, Yingchun, et al. "Plasma Advanced Glycation Endproduct, Methylglyoxal-derived Hydroimidazolone Is Elevated in Young, Complication-free Patients With Type 1 Diabetes." Clinical Biochemistry, vol. 42, no. 7-8, 2009, pp. 562-9.
Han Y, Randell E, Vasdev S, et al. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clin Biochem. 2009;42(7-8):562-9.
Han, Y., Randell, E., Vasdev, S., Gill, V., Curran, M., Newhook, L. A., Grant, M., Hagerty, D., & Schneider, C. (2009). Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clinical Biochemistry, 42(7-8), 562-9. https://doi.org/10.1016/j.clinbiochem.2008.12.016
Han Y, et al. Plasma Advanced Glycation Endproduct, Methylglyoxal-derived Hydroimidazolone Is Elevated in Young, Complication-free Patients With Type 1 Diabetes. Clin Biochem. 2009;42(7-8):562-9. PubMed PMID: 19154730.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. AU - Han,Yingchun, AU - Randell,Edward, AU - Vasdev,Sudesh, AU - Gill,Vicki, AU - Curran,Matthew, AU - Newhook,Leigh Anne, AU - Grant,Marie, AU - Hagerty,Donna, AU - Schneider,Celine, Y1 - 2009/01/03/ PY - 2008/10/27/received PY - 2008/12/22/revised PY - 2008/12/22/accepted PY - 2009/1/22/entrez PY - 2009/1/22/pubmed PY - 2009/6/13/medline SP - 562 EP - 9 JF - Clinical biochemistry JO - Clin. Biochem. VL - 42 IS - 7-8 N2 - OBJECTIVES: Elevated advanced glycation endproducts (AGEs) are implicated in diabetic complications. Methylglyoxal-derived hydroimidazolone (MG-H) is one of the most abundant AGEs in vivo. Our objective was to develop a time-saving, specific method to measure free MG-H in plasma and determine its levels in complication-free young individuals with Type 1 diabetes (T1DM). The relationship of plasma free MG-H to hemoglobin A1C (A1C) and plasma methylglyoxal levels was also determined. DESIGN AND METHODS: A solid phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed, and free plasma MG-H levels were measured in 40 T1DM patients (DM group), aged 6-21 years, and 11 non-diabetics (ND group), 6-22 years. Methylglyoxal was measured using LC-MS/MS and A1C by a Tosoh G7 high-performance liquid chromatograph. RESULTS: Our method showed high recovery, sensitivity and short run-time. Plasma free MG-H (nmol/L) was higher (p<0.001) in the DM group (1318+/-569; mean+/-standard deviation) as compared to the ND group (583+/-419). Within the DM group, plasma free MG-H did not correlate with plasma methylglyoxal or A1C. CONCLUSIONS: Our LC-MS/MS method to measure free MG-H in plasma may be useful for future clinical application. The increased levels of free MG-H observed in individuals with TIDM are not merely the result of short term changes in glucose or methylglyoxal, but may reflect long-term alterations to tissue proteins. SN - 1873-2933 UR - https://www.unboundmedicine.com/medline/citation/19154730/Plasma_advanced_glycation_endproduct_methylglyoxal_derived_hydroimidazolone_is_elevated_in_young_complication_free_patients_with_Type_1_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(08)00641-3 DB - PRIME DP - Unbound Medicine ER -